astrazeneca

Type
Internal restructuring
Country
World
Region
Location of affected unit(s)
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
European Globalisation Fund (EGF)
Year: 2011, Case number: 15
8,000 jobs
Number of planned job losses
Job loss
Announcement Date
28 January 2010
Employment effect (start)
1 February 2010
Foreseen end date
31 January 2014

Description

AstraZeneca has announced plans to reduce its worforce by 8000 over the next four years. The company announced that the job cuts will be made across all regions and divisions. It did not detail the precise effects for units, divisions and countries, apart from stressing that its research & development division will be consolidated. The restructuring might affect 3500 jobs in the research & development division of AstraZeneca, leading to a net job loss in the division of 1800 jobs.  

Citation

Eurofound (2010), astrazeneca, Internal restructuring in World, factsheet number 71706, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/71706.